Understand the source comparison
Follistatin-344 Oral vs Injectable — Real Peptides
Research-grade peptides face a biological barrier most supplement marketing ignores: proteins larger than 50 amino acids are systematically degraded in the gastrointestinal tract. Follistatin-344, a 344-amino-acid glycoprotein that binds and inhibits myostatin
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Research-grade peptides face a biological barrier most supplement marketing ignores: proteins larger than 50 amino acids are systematically degraded in the gastrointestinal tract. Follistatin-344, a 344-amino-acid glycoprotein that binds and inhibits myostatin, activin, and other TGF-β superfamily members, cannot survive gastric transit intact. The proteolytic enzymes pepsin and trypsin cleave peptide bonds indiscriminately. What enters the stomach as a functional follistatin molecule exits as fragmented amino acids with zero biological activity.
- What is the difference between follistatin-344 oral vs injectable?
- Follistatin-344 administered orally is degraded by gastric enzymes before systemic absorption, resulting in near-zero bioavailability. Injectable follistatin-344 bypasses the digestive system entirely, delivering intact peptide to subcutaneous tissue where it enters circulation and binds myostatin receptors. The route of administration determines whether the compound reaches its biological target.
- The distinction isn't semantic. It's pharmacological. Oral peptides marketed as "follistatin boosters" contain fragmented sequences, precursor amino acids, or compounds claimed to upregulate endogenous follistatin expression. None deliver exogenous follistatin-344 to muscle tissue. Injectable formulations, prepared as lyophilised powder and reconstituted with bacteriostatic water, preserve the tertiary protein structure required for receptor binding. This article covers the mechanism behind oral degradation, why subcutaneous injection is the only viable delivery method for exogenous follistatin-344, and what dosing protocols appear in published research.